Belfius Insurance crosses three percent threshold in the equity capital of Ion Beam Applications

Huge Two-Day Clean Sweep Auction July 24-25th. Click Here to Bid!

advertisement
Aktueller Standort:
>
>
> This Story

Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Rad Oncology Homepage

Elekta Unity MR-Linac receives clearance from the Canadian Nuclear Safety Commission

Many of the deadliest cancers receive the least amount of research funding

Swiss Medical Network advances cancer care in Switzerland with multi-system agreement for Accuray radiation therapy systems

MVZ Prof. Dr. Uhlenbrock and Partner select C-RAD’s SIGRT solution

Cyclotron rigging completed in Guangzhou, Guangdong Province, China

Radsource completes 16 ProtonPACS installations in Q2: 2019

RaySearch and Vision RT announce strategic partnership

Sun Nuclear to showcase key quality management advances at AAPM 2019

Elekta to demonstrate leadership in precision radiation medicine at AAPM with launch of new QA portfolio

Johns Hopkins Medicine researchers identify health conditions likely to be misdiagnosed

Belfius Insurance crosses three percent threshold in the equity capital of Ion Beam Applications

Press releases may be edited for formatting or style
Louvain-La-Neuve, Belgium, 18 June 2019 - Belfius Insurance, the insurance branch of Belfius Bank and Insurance, and its shareholder the Belgian Société Fédérale de Participations et d’Investissements (SFPI), are pleased to announce today that they now hold more than 3% of the capital of Ion Beam Applications SA (IBA).

This capital participation is in line with Belfius Bank and Insurance’s strategy to be a privileged partner of Belgian companies and support them in the long run.

Story Continues Below Advertisement

THE (LEADER) IN MEDICAL IMAGING TECHNOLOGY SINCE 1982. SALES-SERVICE-REPAIR

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.



Frédéric Van der Schueren, Chief Financial Officer of Belfius Insurance, commented: “Our participation in IBA’s equity capital perfectly suits our strategy to support and invest in the Belgian economy, and fits our objective to hold a diversified portfolio. Belfius Insurance is proud to support one of Belgium’s technology champions, which is actively fighting cancer.”

Olivier Legrain, Chief Executive Officer of IBA, added, “It is important to IBA that we can count on Belgian partners who share our values and support us in the long run. This allows us to continue innovating and developing cutting-edge technologies to fight cancer and helps us to keep our position of undisputed market leader in all of our markets. Our trusted and long-standing relationship with Belfius enables us to move forward in order to consolidate and develop our activities”


About Belfius Insurance
Belfius Insurance is a subsidiary of Belfius Bank and Insurance, a bank insurer with solid local roots. The group operates in Belgium in three main areas: retail, commercial and private banking, as well as wealth management, financial services for the public and social sector and for corporate clients (wholesale banking) and insurance (Life and Non-Life Products).

Belfius Bank and Insurance is wholly owned by the Belgian State via the The Federal Holding and Investment Company.


About Société Fédérale de Participations et d’Investissements (SFPI)
The Federal Holding and Investment Company (SFPI-FPIM) centrally manages the federal government’s shareholdings, cooperates with the government on specific projects and pursues its own investment policy in the interests of the Belgian economy.


About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,400 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

Rad Oncology Homepage


You Must Be Logged In To Post A Comment